CoChat

Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging

Open access
Wadghiri, Youssef Zaim, Li, Jialin, Wang, Jinhuan, Hoang, Dung Minh, Sun, Yanjie, Xu, Hong, Tsui, Wai, Li, Yongsheng, Boutajangout, Allal, Wang, Andrew, de Leon, Mony, Wisniewski, Thomas · 2013 · PLoS ONE

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Amyloid plaques are a key pathological hallmark of Alzheimer's disease (AD). The detection of amyloid plaques in the brain is important for the diagnosis of AD, as well as for following potential amyloid targeting therapeutic interventions. Our group has developed several contrast agents to detect amyloid plaques in vivo using magnetic resonance microimaging (µMRI) in AD transgenic mice, where we used mannitol to enhance blood brain barrier (BBB) permeability. In the present study, we used bifunctional ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, chemically coupled with Aβ1-42 peptide to image amyloid plaque deposition in the mouse brain. We coupled the nanoparticles to polyethylene glycol (PEG) in order to improve BBB permeability. These USPIO-PEG-Aβ1-42 nanoparticles were injected intravenously in AD model transgenic mice followed by initial in vivo and subsequent ex vivo μMRI. A 3D gradient multi-echo sequence was used for imaging with a 100 µm isotropic resolution. The amyloid plaques detected by T2*-weighted μMRI were confirmed with matched histological sections. The region of interest-based quantitative measurement of T2* values obtained from the in vivo μMRI showed contrast injected AD Tg mice had significantly reduced T2* values compared to wild-type mice. In addition, the ex vivo scans were examined with voxel-based analysis (VBA) using statistical parametric mapping (SPM) for comparison of USPIO-PEG-Aβ1-42 injected AD transgenic and USPIO alone injected AD transgenic mice. The regional differences seen by VBA in the USPIO-PEG-Aβ1-42 injected AD transgenic correlated with the amyloid plaque distribution histologically. Our results indicate that USPIO-PEG-Aβ1-42 can be used for amyloid plaque detection in vivo by intravenous injection without the need to co-inject an agent which increases permeability of the BBB. This technique could aid the development of novel amyloid targeting drugs by allowing therapeutic effects to be followed longitudinally in model AD mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0057097

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Immunoblotting showed the coupling of Aβ1-42 to USPIO using anti-Aβ monoclonal antibody 6E10. Lane 1 shows USPIO-PEG-Aβ1-42 in which Aβ1-42 coupled to nanoparticles is mainly in the stacking gel. A small proportion of Aβ1-42 which was not covalently bound to the particles entered the running gel. Lane 2 shows USPIO alone as negative control, with no bands seen. Lane 3 shows synthetic Aβ1-42 as a positive control, where the two bands seen are monomeric and dimeric Aβ1-42.
Figure 1 Immunoblotting showed the coupling of Aβ1-42 to USPIO using anti-Aβ monoclonal antibody 6E10. Lane 1 shows USPIO-PEG-Aβ1-42 in which Aβ1-42 coupled to nanoparticles is mainly in the stacking gel. A small proportion of Aβ1-42 which was not covalently bound to the particles entered the running gel. Lane 2 shows USPIO alone as negative control, with no bands seen. Lane 3 shows synthetic Aβ1-42 as a positive control, where the two bands seen are monomeric and dimeric Aβ1-42.CC BY · PubMed Central
Figure 2 A shows the binding between USPIO-PEG-Aβ1-42 and Aβ1-40 assessed by ELISA. The KD of USPIO-PEG-Aβ1-42 to Aβ1-40 binding was calculated to be 206.7nM±42.09. B shows a bar graph illustrating tissue culture toxicity studies using USPIO-PEG-Aβ1-42, Aβ1-42 alone and uncoupled USPIO on N2a cells (mean ± s.d.). Cell viability of untreated control cells is set at 100%. There was no evidence of significant toxicity of USPIO-PEG-Aβ1-42 at a concentration of 10 µM as compared to Aβ1-42 alone at the same 10 µM concentration, under these conditions. No toxicity of USPIO particles alone was evident. One way ANOVA analysis gave a p<0.0001 for a difference between the groups. Newman-Keuls post-hoc analysis showed Aβ1-42 versus control, Aβ1-42 versus USPIO-PEG-Aβ1-42 and Aβ1-42 versus USPIO to be significantly different (p<0.001, p<0.001, p<0.001, respectively). USPIO alone versus control untreated cells, USPIO-PEG-Aβ1-42 versus control untreated cells and USPIO versus USPIO-PEG-Aβ1-42 did not differ significantly. NS: not significant.
Figure 2 A shows the binding between USPIO-PEG-Aβ1-42 and Aβ1-40 assessed by ELISA. The KD of USPIO-PEG-Aβ1-42 to Aβ1-40 binding was calculated to be 206.7nM±42.09. B shows a bar graph illustrating tissue culture toxicity studies using USPIO-PEG-Aβ1-42, Aβ1-42 alone and uncoupled USPIO on N2a cells (mean ± s.d.). Cell viability of untreated control cells is set at 100%. There was no evidence of significant toxicity of USPIO-PEG-Aβ1-42 at a concentration of 10 µM as compared to Aβ1-42 alone at the same 10 µM concentration, under these conditions. No toxicity of USPIO particles alone was evident. One way ANOVA analysis gave a p<0.0001 for a difference between the groups. Newman-Keuls post-hoc analysis showed Aβ1-42 versus control, Aβ1-42 versus USPIO-PEG-Aβ1-42 and Aβ1-42 versus USPIO to be significantly different (p<0.001, p<0.001, p<0.001, respectively). USPIO alone versus control untreated cells, USPIO-PEG-Aβ1-42 versus control untreated cells and USPIO versus USPIO-PEG-Aβ1-42 did not differ significantly. NS: not significant.CC BY · PubMed Central
Figure 3 Amyloid plaques were detected with in vivo µMRI after intravenous femoral injection of USPIO-PEG-Aβ1-42. In vivo T2*-weighted μMRI images show a 14 month-old APP/PS1 Tg mouse. B shows a higher magnification of the area in the red box of shown in A. C shows the matching tissue section to A immunolabeled with anti-Aβ 4G8/6E10. D shows a higher magnification of the area in the red box of C. Arrowhead highlight some of the matching dark spots seen by μMRI with the immunolabeled tissue sections.
Figure 3 Amyloid plaques were detected with in vivo µMRI after intravenous femoral injection of USPIO-PEG-Aβ1-42. In vivo T2*-weighted μMRI images show a 14 month-old APP/PS1 Tg mouse. B shows a higher magnification of the area in the red box of shown in A. C shows the matching tissue section to A immunolabeled with anti-Aβ 4G8/6E10. D shows a higher magnification of the area in the red box of C. Arrowhead highlight some of the matching dark spots seen by μMRI with the immunolabeled tissue sections.CC BY · PubMed Central
Figure 4 Shows an in vivo μMRI of a 16 month old wild-type mouse after intravenous femoral injection of USPIO-PEG-Aβ1-42. B shows a higher magnification of the area in the red box of shown in A. Some dark spots are also evident in A (likely corresponding to blood vessels) but far fewer than seen in Figure 3A or Figure 4A . C shows the matching tissue section to A immunolabeled with anti-Aβ 4G8/6E10. No amyloid deposits are evident, as expected.
Figure 4 Shows an in vivo μMRI of a 16 month old wild-type mouse after intravenous femoral injection of USPIO-PEG-Aβ1-42. B shows a higher magnification of the area in the red box of shown in A. Some dark spots are also evident in A (likely corresponding to blood vessels) but far fewer than seen in Figure 3A or Figure 4A . C shows the matching tissue section to A immunolabeled with anti-Aβ 4G8/6E10. No amyloid deposits are evident, as expected.CC BY · PubMed Central
Figure 5 Shows an ex vivo μMRI coronal cut at the level of the anterior hippocampus of a 15 month-old APP/PS1 Tg injected with USPIO-PEG-Aβ1-42, showing numerous dark spots. In B1 a higher magnification of the μMRI in the red box in A is shown. This is matched to amyloid plaque immunolabeling (in red) shown in B2. Arrows highlight some matches between the μMRI and histology. Figure C1 is higher magnification of the μMRI in the green box in A. This is matched to double amyloid plaque immunolabeling and Perl iron staining in C2 and C3. Arrows highlight some of the matches between the μMRI in C1 and immunolabeling in C2. C3 is a higher magnification of the black box in C2. C4 shows and example of double amyloid plaque immunolabeling and Perl iron staining in an APP/PS1 mouse injected with USPIO alone. Only the red immunolabeling of amyloid plaques is seen with no co-label of iron. Co-labeling of amyloid plaques with anti-Aβ 4G8/6E10 (in red) and Perl iron stain (in blue) highlights the co-deposition of USPIO-PEG-Aβ1-42 on amyloid deposits in C2 and C3 (scale bar = 100 microns).
Figure 5 Shows an ex vivo μMRI coronal cut at the level of the anterior hippocampus of a 15 month-old APP/PS1 Tg injected with USPIO-PEG-Aβ1-42, showing numerous dark spots. In B1 a higher magnification of the μMRI in the red box in A is shown. This is matched to amyloid plaque immunolabeling (in red) shown in B2. Arrows highlight some matches between the μMRI and histology. Figure C1 is higher magnification of the μMRI in the green box in A. This is matched to double amyloid plaque immunolabeling and Perl iron staining in C2 and C3. Arrows highlight some of the matches between the μMRI in C1 and immunolabeling in C2. C3 is a higher magnification of the black box in C2. C4 shows and example of double amyloid plaque immunolabeling and Perl iron staining in an APP/PS1 mouse injected with USPIO alone. Only the red immunolabeling of amyloid plaques is seen with no co-label of iron. Co-labeling of amyloid plaques with anti-Aβ 4G8/6E10 (in red) and Perl iron stain (in blue) highlights the co-deposition of USPIO-PEG-Aβ1-42 on amyloid deposits in C2 and C3 (scale bar = 100 microns).CC BY · PubMed Central
Figure 6 Shows an example of ex vivo μMRI, at the level of the area cinguli of the cerebral cortex, of a 14 month-old APP/PS1 Tg injected with USPIO-PEG-Aβ1-42, showing numerous dark spots. This is matched to a tissue section immunolabeled with anti-Aβ 4G8/6E10 in B. C is higher magnification of the μMRI in the red box in A, while D is a higher magnification of the tissue section immunolabeling seen in B.
Figure 6 Shows an example of ex vivo μMRI, at the level of the area cinguli of the cerebral cortex, of a 14 month-old APP/PS1 Tg injected with USPIO-PEG-Aβ1-42, showing numerous dark spots. This is matched to a tissue section immunolabeled with anti-Aβ 4G8/6E10 in B. C is higher magnification of the μMRI in the red box in A, while D is a higher magnification of the tissue section immunolabeling seen in B.CC BY · PubMed Central
Figure 7 Shows areas of the brain are shown which differed by voxel-based analysis of ex vivo μMRI comparing USPIO-PEG-Aβ1-42 injected APP/PS1 Tg mice (n = 12) and APP/PS1 Tg mice (n = 12) injected with USPIO alone (p<0.01). The regions of differences mirror the distribution of amyloid plaques histologically, being mainly in the cortex and hippocampus. Color bar units are the T-score. A shows areas which are significantly different in coronal sections, while B shows areas which are significantly different in horizontal sections.
Figure 7 Shows areas of the brain are shown which differed by voxel-based analysis of ex vivo μMRI comparing USPIO-PEG-Aβ1-42 injected APP/PS1 Tg mice (n = 12) and APP/PS1 Tg mice (n = 12) injected with USPIO alone (p<0.01). The regions of differences mirror the distribution of amyloid plaques histologically, being mainly in the cortex and hippocampus. Color bar units are the T-score. A shows areas which are significantly different in coronal sections, while B shows areas which are significantly different in horizontal sections.CC BY · PubMed Central
Figure 8 Shows areas of the brain are shown which differed by voxel-based analysis of ex vivo μMRI comparing USPIO-PEG-Aβ1-42 injected APP/PS1 Tg mice (n = 12) and wild-type mice (n = 12) injected with USPIO-PEG-Aβ1-42 (p<0.05). The regions of differences mirror the distribution of amyloid plaques histologically, being mainly in the cortex and hippocampus. Color bar units are the T-score. A shows areas which are significantly different in coronal sections, while B shows areas which are significantly different in horizontal sections.
Figure 8 Shows areas of the brain are shown which differed by voxel-based analysis of ex vivo μMRI comparing USPIO-PEG-Aβ1-42 injected APP/PS1 Tg mice (n = 12) and wild-type mice (n = 12) injected with USPIO-PEG-Aβ1-42 (p<0.05). The regions of differences mirror the distribution of amyloid plaques histologically, being mainly in the cortex and hippocampus. Color bar units are the T-score. A shows areas which are significantly different in coronal sections, while B shows areas which are significantly different in horizontal sections.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. M Sadowski, 2006, Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice, Proc Natl Acad Sci (USA), 103(49), 18787

Cited by

See all 119

Metadata

Authors
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., de Leon, M., & Wisniewski, T.
Affiliations
  • New York University (US)
  • Tianjin Huanhu Hospital (CN)
  • Ocean NanoTech (United States) (US)
Corresponding author
Wadghiri, Youssef Zaim
Venue
PLoS ONE
Published
2013-02-27
Volume
8
Issue
2
Pages
e57097
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2024542897
Cited by
114
References
54
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 11 · 2021: 2 · 2020: 8 · 2019: 11 · 2018: 11 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 15 · 2013: 3
FWCI
9.03
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Health Assistance Foundation (A2008-155)
  • Tianjin Science and Technology Committee
  • National Institutes of Health
  • National Institute on Aging (AG20245, P30AG008051, R01AG020245)
  • National Cancer Institute (P30CA016087)
  • National Institute of Neurological Disorders and Stroke (NS073502, R01NS073502)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
Keywords
amyloid plaques, Alzheimer's disease, ultrasmall superparamagnetic iron oxide, blood-brain barrier permeability, polyethylene glycol, anti-amyloid therapy, T2 contrast, transgenic mouse model, ex vivo imaging
MeSH terms
Alzheimer Disease, Animals, Brain, Contrast Media, Disease Models, Animal, Magnetic Resonance Imaging, Mice, Transgenic, Amyloid beta-Peptides, Mice, Magnetite Nanoparticles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging. https://app.cochat.ai/papers/10.1371/journal.pone.0057097
The paper
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., de Leon, M., & Wisniewski, T. (2013). Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging. PLoS ONE. https://doi.org/10.1371/journal.pone.0057097

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.